Last reviewed · How we verify
NCT03610035
A Study of NPT189 in Healthy Subjects
Phase 1 trial testing NPT189 in Amyloidosis in 48 participants. Completed in 17 February 2019.
17 February 2019
Quick facts
| Lead sponsor | Proclara Biosciences, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 24 July 2018 |
| Primary completion | 17 February 2019 |
| Estimated completion | 17 February 2019 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- NPT189 — full drug profile →
- Placebo
Conditions studied
- Amyloidosis — all drugs for Amyloidosis →
Sponsor
Proclara Biosciences, Inc. — full company profile →
Who can join
Adults 18 to 65, any sex, with Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to evaluate the safety and tolerability of single dose of NPT189 in healthy volunteers. The study will also evaluate the pharmacokinetic characteristics of NPT189.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.
Plotkin SS, Cashman NR. · · 2020 · cited 106× · PMID 32682954 · DOI 10.1016/j.nbd.2020.105010
Verify or expand the search:
- PubMed search for NCT03610035
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of NPT189
Trials testing the same drug.
- NCT03879278 — Multiple Ascending Dose Study in Healthy Subjects · Phase 1 · terminated
Other recruiting trials for Amyloidosis
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
Other Proclara Biosciences, Inc. trials
Trials by the same sponsor.
- NCT03879278 — Multiple Ascending Dose Study in Healthy Subjects · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03610035 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Proclara Biosciences, Inc.
- Last refreshed: 15 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03610035.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing